NCT00343759撤回2 期
Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- Change in downstream effector levels in biologic responders to lapatinib as determined by degree of change in proliferation and apoptosis compared to biologic non-responders.
研究概览
简要总结
The purpose of this study is to see what kinds of breast tumors will respond to lapatinib. Lapatinib is an experimental medicine which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically-confirmed by either core or fine needle biopsy primary invasive carcinoma of the breast;
- •AJCC T2-T3 disease (>2.0 cm without chest wall or skin invasion) by at least one imaging modality (either mammogram, ultrasound, or MRI) - entry criteria is based on radiologic staging and not final pathologic staging;
- •ECOG performance status 0-1 (Karnofsky ≥ 70%
- •Any lymph node status, hormone receptor status, and level of erbB2 expression
- •No prior chemotherapy, hormonal therapy or radiation therapy to the affected breast for current or previous malignancy;
- •Cardiac ejection fraction >50% or within the institutional range of normal;
- •Patients must have normal organ and marrow function defined as: Leukocyte count >3000/uL; Absolute neutrophil count (ANC) ≥ 1,500/mm3, platelets > 100,000/mm3, and hemoglobin ≥ 8 gm/dl; Serum creatinine ≤ 1.5 times ULN, or 24-hour creatinine clearance ≥ 75 cc/min; Serum bilirubin ≤ 1.5 times ULN; SGOT ≤ 2.5 times ULN; alkaline phosphatase ≤ 2.5 ULN times ULN.
- •The effects of lapatinib on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- •Ability to understand and the willingness to sign written informed consent document.
排除标准
- •AJCC T1, T4, or stage 4 disease;
- •Patients may not have undergone incisional or excisional biopsy of their tumor;
- •Patients may not be receiving any other investigational agents;
- •Absolute contraindication to MRI imaging (cardiac pacemaker or any non-removable metallic foreign object in the body);
- •On chronic therapy with any known inducer or inhibitor of CYP3A4
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant or lactating women are excluded from this study because lapatinib is a tyrosine kinase inhibitor with the potential for teratogenic or abortifacient effects.
结局指标
主要结局
Change in downstream effector levels in biologic responders to lapatinib as determined by degree of change in proliferation and apoptosis compared to biologic non-responders.
时间窗: Study completion
次要结局
- To describe the biologic response rate, defined by induction of apoptosis, to Lapatinib in a pre-surgical, treatment-naïve breast cancer population.(Study completion)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
2 期
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)Breast CancerNCT02764541Dana-Farber Cancer Institute195
进行中（未招募）
1 期
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal AdenocarcinomaAdenocarcinomaTumorNCT05273554M.D. Anderson Cancer Center15
已完成
2 期
Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast CancerBreast CancerNCT00299286Institute of Cancer Research, United Kingdom121
已完成
1 期
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal DiseaseAnemia of Chronic Kidney DiseaseNCT02581124Akros Pharma Inc.10
已完成
1 期
Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast CancerBreast CancerNCT00513058UNICANCER33